AS
NBIX icon

Aware Super’s Neurocrine Biosciences NBIX Stock Holding History

Aware Super’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$22.1M Sell
130,870
-5,916
-4% -$878K 0.31% 87
2026
Q1 		$18M Buy
+136,786
New +$18.1M 0.27% 97
2025
Q3 		$15.2M Buy
108,364
+70,569
+187% +$9.56M 0.21% 116
2025
Q2 		$4.75M Buy
37,795
+22,125
+141% +$2.54M 0.07% 175
2025
Q1 		$1.73M Hold
15,670
– – 0.03% 216
2024
Q4 		$2.14M Buy
+15,670
New +$1.94M 0.03% 209
2023
Q4 		$20.5M Buy
+144,875
New +$16.7M 0.27% 96

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Aware Super's NBIX Position: Q2 2026 in Review

Aware Super reduced its Neurocrine Biosciences (NBIX) stake by 4.3% in Q2 2026, selling an estimated $878K and leaving 130,870 shares worth $22.1M. The position accounts for 0.31% of the portfolio, ranked #87.

Aware Super first reported a position in NBIX in Q4 2023 and has held it in 7 quarters since. 776 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Aware Super held 130,870 shares of Neurocrine Biosciences worth $22.1M as of Q2 2026.
  • Aware Super sold 5,916 Neurocrine Biosciences shares in Q2 2026, an estimated $878K.
  • Neurocrine Biosciences made up 0.31% of Aware Super's portfolio in Q2 2026, its #87 holding.
  • Aware Super first reported a position in Neurocrine Biosciences in Q4 2023 and has held it in 7 quarters since.
  • 776 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Aware Super's 13F filing for Q2 2026, filed 29 Jul 2026.